儿童脑肿瘤细胞表面抗原图谱:B7-H3持续表达并可经局部或全身CAR T细胞递送靶向
该研究通过流式分析49例儿童脑肿瘤患者来源的原位异种移植瘤(PDOX),检测5种CAR靶抗原及HLA I类分子表达。结果显示抗原表达呈层级分布且异质,B7-H3与GD2表达最高;B7-H3-CAR T细胞在PDOX和免疫健全小鼠胶质瘤模型中经局部或全身给药均诱导肿瘤消退并显著延长生存。
要点
- 儿童脑肿瘤PDOX中B7-H3与GD2表达最高,抗原表达存在异质性。
- 所有高级别胶质瘤表达HLA I类,其他亚型仅57.1%可检测到。
- B7-H3-CAR T细胞局部或全身给药均诱导肿瘤消退并延长生存。
核心结论
- B7-H3在儿童脑肿瘤中持续表达,可作为CAR T细胞治疗的候选靶点。
- 局部或全身递送B7-H3-CAR T细胞在临床前模型中诱导肿瘤消退并带来显著生存优势。
研究设计与样本
- 研究对49例儿童低级别和高级别脑肿瘤患者来源的原位异种移植瘤(PDOX)进行流式分析。
- 检测5种CAR靶抗原(B7-H3、GD2、IL-13Rα2、EphA2、HER2)及HLA I类分子表达。
- 生成B7-H3-CAR T细胞并在体外及PDOX和免疫健全小鼠胶质瘤模型中评估抗肿瘤活性。
主要发现
- 抗原表达层级为B7-H3 = GD2 >> IL-13Rα2 > HER2 = EphA2,且抗原表达异质。
- 所有高级别胶质瘤表达HLA I类,其他肿瘤亚型仅57.1%可检测到HLA I类表达。
- B7-H3-CAR T细胞以抗原依赖方式识别肿瘤细胞。
- 局部或全身给予B7-H3-CAR T细胞使PDOX和免疫健全小鼠胶质瘤模型肿瘤消退并显著延长生存。
关键数值与推荐
- 49例儿童脑肿瘤PDOX中,高级别胶质瘤全部表达HLA I类,其他亚型57.1%可检测到表达。
- 5种CAR靶抗原表达层级:B7-H3 = GD2 >> IL-13Rα2 > HER2 = EphA2。
临床怎么用
- 儿童脑肿瘤免疫治疗设计前应评估PDOX样本中靶抗原和HLA I类表达。
- B7-H3可作为广谱儿童脑肿瘤CAR T细胞治疗的临床前和临床探索靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy with chimeric antigen receptor (CAR) T cells is actively being explored for pediatric brain tumors in preclinical models and early phase clinical studies. At present, it is unclear which CAR target antigens are consistently expressed across different pediatric brain tumor types. In addition, the extent of HLA class I expression is unknown, which is critical for tumor recognition by conventional αβTCR T cells. METHODS: We profiled 49 low- and high-grade pediatric brain tumor patient-derived orthotopic xenografts (PDOX) by flow analysis for the expression of 5 CAR targets (B7-H3, GD2, IL-13Rα2, EphA2, and HER2), and HLA class I. In addition, we generated B7-H3-CAR T cells and evaluated their antitumor activity in vitro and in vivo. RESULTS: We established an expression hierarchy for the analyzed antigens (B7-H3 = GD2 >> IL-13Rα2 > HER2 = EphA2) and demonstrated that antigen expression is heterogenous. All high-grade gliomas expressed HLA class I, but only 57.1% of other tumor subtypes had detectable expression. We then selected B7-H3 as a target for CAR T-cell therapy. B7-H3-CAR T cells recognized tumor cells in an antigen-dependent fashion. Local or systemic administration of B7-H3-CAR T cells induced tumor regression in PDOX and immunocompetent murine glioma models resulting in a significant survival advantage. CONCLUSIONS: Our study highlights the importance of studying target antigen and HLA class I expression in PDOX samples for the future design of immunotherapies. In addition, our results support active preclinical and clinical exploration of B7-H3-targeted CAR T-cell therapies for a broad spectrum of pediatric brain tumors.
引用
- Haydar D, Houke H, Chiang J, et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 2021. PMID: 33320196. doi:10.1093/neuonc/noaa278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。